Trial · NCT03968237
Measures to Improve Outcomes After an Opioid Overdose
NCT03968237, Withdrawn, Nassima Ait-Daoud Tiouririne
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Measures to Improve Outcomes After an Opioid Overdose. Trials, record NCT03968237. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03968237
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Measures to Improve Outcomes After an Opioid Overdose
- NCT number
- NCT03968237
- Status
- Withdrawn
- Enrollment
- 0 participants, actual
- Lead sponsor
- Nassima Ait-Daoud Tiouririne
- Conditions
- Opioid Overdose
- Interventions
- Buprenorphine/Naloxone
- First posted
- 2019-05-30
- Last updated
- 2026-06-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Opiate Withdrawal Scale (COWS) | at screening | The COWS is an 11 item scale designed to be administered by a clinican. This tool is used to rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. Reduction in adverse events will be evaluated by the documentation of COWS scores right after administration of Naloxone, then buprenorphine/naloxone. |
| Primary | Opioid Related Emergency Department (ED) Visits | up to 30 days | Reduce risk of opioid re-overdose following ED buprenorphine/naloxone induction protocol. This will be measured by calculating the percentage of opioid related visits to any ED at 7 days post discharge, at 30 days post discharge, and hospital admissions at 30 days discharge. |
| Primary | Treatment Engagement | up to 6 months | Improve addiction treatment engagement for patients receiving ED buprenorphine/naloxone induction following opioid overdose. This will be measured by the number of ED patients scheduled for follow-up at the office based opioid treatment (OBOT) clinic versus number of patients that attend the scheduled first appointment and number of patients that continue to follow-up at the OBOT clinic at 30 days and at 6 months. |
| Secondary | Demographic Data | at screening | The investigator will collect the demographic data of the population served by this protocol. |
| Secondary | Brief Addiction Monitor (BAM) | up to 6 months | Report of substance use and social and health outcomes. It is a 17 item, multidimensional questionnaire which assess three substance use disorder related aspects (risk factors for substance use, protective factors that support sobriety, and drug and alcohol use). |
| Secondary | Urine Drug Screen | up to 6 months | Percentage of urine toxicology positive for illicit drug and opioid use. |
| Secondary | HIV Risk-Taking Behavioral Scale HIV Risk-Taking Behavioral Scale | up to 6 months | Social and Health Outcomes. It is an 11 item validated scale for drug use and sexual behavior. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03968237
GET https://conductscience.org/api/trials/v1/NCT03968237/registered